Five-year data show gene therapy safe for ND4-LHON
GenSight Biologics has revealed pooled safety data from five clinical studies of lenadogene nolparvovec (Lumevoq), the largest cohort of ND4-LHON (Leber hereditary optic neuropathy) patients studied after gene therapy treatment. The data confirms the good overall safety profile of the product in terms of systemic and… Read More